
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.





























